Quick Answer
Relay Therapeutics, Inc. reported Stockholders Equity of $567.06 million for the year ending 2025.
- Relay Therapeutics, Inc. showed a decrease of -27.1% in Stockholders Equity from 2024 to 2025.
- This data is from Relay Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$124.16 million | Q2 2019: -$140.02 million | Q3 2019: -$158.29 million | Q1 2020: -$202.35 million | Q2 2020: -$225.39 million | Q3 2020: $713.53 million | Q1 2021: $732.79 million | Q2 2021: $618.53 million | Q3 2021: $571.09 million | Q1 2022: $841.97 million | Q2 2022: $779.64 million | Q3 2022: $999.77 million | Q1 2023: $883.41 million | Q2 2023: $810.12 million | Q3 2023: $778.37 million | Q1 2024: $745.76 million | Q2 2024: $681.74 million | Q3 2024: $838.86 million | Q1 2025: $721.08 million | Q2 2025: $665.66 million | Q3 2025: $607.71 million.
- Over the full 8 years of available data (2018 to 2025), Relay Therapeutics, Inc.'s Stockholders Equity has grown by 611.2%.
- Historical annual values: Fiscal year 2025: $567.06 million | Fiscal year 2024: $777.79 million | Fiscal year 2023: $752.00 million | Fiscal year 2022: $950.22 million | Fiscal year 2021: $897.81 million | Fiscal year 2020: $763.29 million | Fiscal year 2019: -$180.44 million | Fiscal year 2018: -$110.93 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: